研究者データベース

櫻井 俊宏(サクライ トシヒロ)
保健科学研究院 保健科学部門 病態解析学分野
講師

基本情報

所属

  • 保健科学研究院 保健科学部門 病態解析学分野

職名

  • 講師

学位

  • 博士(保健科学)(北海道大学)

科研費研究者番号

  • 60707602

J-Global ID

プロフィール

  • 2006年取得 臨床検査技師(登録番号:160066)

    2007年取得 第2種ME技術者(登録番号:2070623)

    2018年取得 健康食品管理士 認定資格(登録番号:11656)

    2018年修了 厚生労働省大臣の指定する「検体採取並びに味覚検査及び嗅覚検査の実施に必要な知識及び技能取得講習会」(登録番号:49000)

研究キーワード

  • LDL−TG   HDL   LDL   肝臓   分析   臨床検査   食品   酸化ストレス   リポタンパク質   脂質   

研究分野

  • ライフサイエンス / 食品科学
  • ライフサイエンス / 代謝、内分泌学
  • ライフサイエンス / 栄養学、健康科学
  • ライフサイエンス / 消化器内科学
  • その他 / その他 / 病態検査学

職歴

  • 2016年11月 - 現在 北海道大学大学院保健科学研究院 病態解析学分野 講師
  • 2016年06月 - 2016年10月 北海道大学大学院保健科学研究院 健康科学分野 助教
  • 2013年06月 - 2016年05月 National Institutes of Health Dr. Alan Remaley’s laboratory Postdoctoral fellow
  • 2013年04月 - 2013年05月 北海道大学保健科学研究院 惠 淑萍研究室 博士研究員
  • 2011年04月 - 2013年03月 日本学術振興会特別研究員 DC

学歴

  • 2010年04月 - 2013年03月   北海道大学   大学院保健科学院   博士後期課程
  • 2008年04月 - 2010年03月   北海道大学   大学院保健科学院   博士前期課程
  • 2006年04月 - 2008年03月   北海道大学   医学部   保健学科検査技術科学専攻(三年次編入)
  • 2003年04月 - 2006年03月   北海道大学   医療技術短期大学部   衛生技術学科

所属学協会

  • 日本医用マススペクトル学会   American Association for Clinical Chemistry   日本臨床検査医学会   日本臨床化学会   

研究活動情報

論文

  • Shrestha R, Chen Z, Miura Y, Yamamoto Y, Sakurai T, Chiba H, Hui SP
    Annals of clinical biochemistry 57 1 95 - 98 2020年01月 [査読有り][通常論文]
  • Yifan Chen, Shu Ping Hui, Yusuke Miura, Sota Kato, Toshihiro Sakurai, Zhen Chen, Emiko Okada, Shigekazu Ukawa, Takafumi Nakagawa, Koshi Nakamura, Akiko Tamakoshi, Hitoshi Chiba, Hiroyuki Minami, Masahiro Mizuta
    Analytical sciences : the international journal of the Japan Society for Analytical Chemistry 2019年11月15日 [査読有り][通常論文]
  • Kenji Nishimura, Taichi Murakami, Toshihiro Sakurai, Masashi Miyoshi, Kiyoe Kurahashi, Seiji Kishi, Masanori Tamaki, Tatsuya Tominaga, Sumiko Yoshida, Kojiro Nagai, Hideharu Abe, Shu-Ping Hui, Kazuhiko Kotani, Toshio Doi
    Scientific reports 9 1 14869 - 14869 2019年10月16日 [査読有り][通常論文]
     
    Circulating ApolipoproteinL1 (ApoL1) is a component of pre-β-high-density lipoprotein (HDL), however little is known about the relationship of ApoL1 with cardiometabolic factors. Considering previous studies reporting the correlation of ApoL1 to triglyceride, we have hypothesized that ApoL1 associates with insulin-related metabolism. The current study examined their associations in 126 non-diabetic subjects and 36 patients with type 2 diabetes (T2DM). Non-diabetic subjects demonstrated triglyceride (standardized coefficients [s.c.] = 0.204, p < 0.05), body mass index (s.c. =0.232, p < 0.05) and HDL cholesterol (s.c. = -0.203, p < 0.05) as independent determinant of ApoL1 levels, and the significant elevation of ApoL1 in metabolic syndrome. Lipoprotein fractionation analysis revealed the predominant distribution of ApoL1 in large HDL fraction, and the significant increase of ApoL1 in large LDL fraction in high ApoL1 samples with insulin resistance. In T2DM, ApoL1 was higher in T2DM with metabolic syndrome, however ApoL1 was lower with β cell dysfunction. Insulin significantly promotes ApoL1 synthesis and secretion in HepG2 cells. In conclusion, circulating ApoL1 may be associated with abnormal HDL metabolism in insulin resistant status. This may suggest a regulation of insulin signal on the ApoL1 level, leading to offer a novel insight to the ApoL1 biology.
  • Tsukui T, Chen Z, Fuda H, Furukawa T, Oura K, Sakurai T, Hui SP, Chiba H
    Journal of agricultural and food chemistry 67 35 9934 - 9941 2019年09月 [査読有り][通常論文]
  • Journal of the Science of Food and Agriculture 2019年03月 [査読有り][通常論文]
  • Ikuta A, Sakurai T, Nishimukai M, Takahashi Y, Nagasaka A, Hui SP, Hara H, Chiba H
    Clinica chimica acta; international journal of clinical chemistry 2019年02月 [査読有り][通常論文]
  • Komatsu T, Sakurai T, Wolska A, Amar M, Sakurai A, Vaisman B, Sviridov D, Demosky S, Pryor M, Ikewaki K, Remaley AT
    Journal of Nutrition and Metabolism 2019 7078241  2019年01月 [査読有り][通常論文]
  • Sakurai T, Hayasaka T, Sekiguchi H, Satoh H, Chen Z, Chiba H, Hui SP
    Journal of the science of food and agriculture Wiley 2018年09月 [査読有り][通常論文]
  • Takahashi Y, Ito Y, Sakurai T, Wada N, Nagasaka A, Fujikawa M, Chiba H, Hui SP
    Annals of clinical biochemistry 4563218795212  2018年08月 [査読有り][通常論文]
  • Sakurai T, Sakurai A, Vaisman BL, Nishida T, Neufeld EB, Demosky SJ Jr, Sampson ML, Shamburek RD, Freeman LA, Remaley AT
    Annals of clinical biochemistry 55 4 414 - 421 2018年07月 [査読有り][通常論文]
  • Takeda S, Sakurai T, Hui SP, Fuda H, Chiba H
    Biochemical and biophysical research communications 501 3 607 - 611 2018年06月 [査読有り][通常論文]
  • Sakurai T, Sakurai A, Chen Y, Vaisman BL, Amar MJ, Pryor M, Thacker SG, Zhang X, Wang X, Zhang Y, Zhu J, Yang ZH, Freeman LA, Remaley AT
    Molecular nutrition & food research 61 8 2017年08月 [査読有り][通常論文]
     
    Scope: alpha-Cyclodextrin (alpha-CD), a cyclic polymer of glucose, has been shown to lower plasma cholesterol in animals and humans; however, its effect on atherosclerosis has not been previously described. Methods and results: apoE-knockout mice were fed either low-fat diet (LFD; 5.2% fat, w/w), or Western high fat diet (21.2% fat) containing either no additions (WD), 1.5% alpha-CD (WDA); 1.5% beta-CD (WDB); or 1.5% oligofructose-enriched inulin (WDI). Although plasma lipids were similar after 11 weeks on theWDvs. WDA diets, aortic atherosclerotic lesions were 65% less in mice on WDA compared toWD (P < 0.05), and similar tomice fed the LFD. No effect on atherosclerosis was observed for the other WD supplemented diets. By RNA-seq analysis of 16S rRNA, addition of alpha-CD to the WD resulted in significantly decreased cecal bacterial counts in genera Clostridium and Turicibacterium, and significantly increased Dehalobacteriaceae. At family level, Comamonadaceae significantly increased and Peptostreptococcaceae showed a negative trend. Several of these bacterial count changes correlated negatively with % atherosclerotic lesion and were associated with increased cecum weight and decreased plasma cholesterol levels. Conclusion: Addition of alpha-CD to the diet of apoE-knockoutmice decreases atherosclerosis and is associated with changes in the gut flora.
  • Zhi-Hong Yang, Masahiro Bando, Toshihiro Sakurai, Ye Chen, Beatrice Emma-Okon, Bree Wilhite, Daiju Fukuda, Boris Vaisman, Milton Pryor, Yoshiyuki Wakabayashi, Maureen Sampson, Zu-Xi Yu, Akiko Sakurai, Abdalrahman Zarzour, Hiroko Miyahara, Jiro Takeo, Hiroshi Sakaue, Masataka Sata, Alan T. Remaley
    MOLECULAR NUTRITION & FOOD RESEARCH 60 10 2208 - 2218 2016年10月 [査読有り][通常論文]
     
    Scope: Fish oil-derived long-chain monounsaturated fatty acids (LCMUFA) containing chain lengths longer than 18 were previously shown to improve cardiovascular disease risk factors in mice. However, it is not known if LCMUFA also exerts anti-atherogenic effects. The main objective of the present study was to investigate the effect of LCMUFA on the development of atherosclerosis in mouse models. Methods and results: LDLR-KO mice were fed Western diet supplemented with 2% (w/w) of either LCMUFA concentrate, olive oil, or not (control) for 12 wk. LCMUFA, but not olive oil, significantly suppressed the development of atherosclerotic lesions and several plasma inflammatory cytokine levels, although there were no major differences in plasma lipids between the three groups. At higher doses 5% (w/w) LCMUFA supplementation was observed to reduce pro-atherogenic plasma lipoproteins and to also reduce atherosclerosis in ApoE-KO mice fed a Western diet. RNA sequencing and subsequent qPCR analyses revealed that LCMUFA upregulated PPAR signaling pathways in liver. In cell culture studies, apoB-depleted plasma from LDLR-K mice fed LCMUFA showed greater cholesterol efflux from macrophage-like THP-1 cells and ABCA1-overexpressing BHK cells. Conclusion: Our research showed for the first time that LCMUFA consumption protects against diet-induced atherosclerosis, possibly by upregulating the PPAR signaling pathway.
  • Toshihiro Sakurai, Akiko Sakurai, Boris L. Vaisman, Marcelo J. Amar, Chengyu Liu, Scott M. Gordon, Steven K. Drake, Milton Pryor, Maureen L. Sampson, Ling Yang, Lita A. Freeman, Alan T. Remaley
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 356 2 341 - 353 2016年02月 [査読有り][通常論文]
     
    Apolipoprotein C-II (apoC-II) is a cofactor for lipoprotein lipase, a plasma enzyme that hydrolyzes triglycerides (TGs). ApoC-II deficiency in humans results in hypertriglyceridemia. We used zinc finger nucleases to create Apoc2 mutant mice to investigate the use of C-II-a, a short apoC-II mimetic peptide, as a therapy for apoC-II deficiency. Mutant mice produced a form of apoC-II with an uncleaved signal peptide that preferentially binds high-density lipoproteins (HDLs) due to a 3-amino acid deletion at the signal peptide cleavage site. Homozygous Apoc2 mutant mice had increased plasma TG (757.5 +/- 281.2 mg/dl) and low HDL cholesterol (31.4 +/- 14.7 mg/dl) compared with wild-type mice (TG, 55.9 +/- 13.3 mg/dl; HDL cholesterol, 55.9 +/- 14.3 mg/dl). TGs were found in light (density < 1.063 g/ml) lipoproteins in the size range of very-low-density lipoprotein and chylomicron remnants (40-200 nm). Intravenous injection of C-II-a (0.2, 1, and 5 mu mol/kg) reduced plasma TG in a dose-dependent manner, with a maximum decrease of 90% occurring 30 minutes after the high dose. Plasma TG did not return to baseline until 48 hours later. Similar results were found with subcutaneous or intramuscular injections. Plasma half-life of C-II-a is 1.33 +/- 0.72 hours, indicating that C-II-a only acutely activates lipolysis, and the sustained TG reduction is due to the relatively slow rate of new TG-rich lipoprotein synthesis. In summary, we describe a novel mouse model of apoC-II deficiency and show that an apoC-II mimetic peptide can reverse the hypertriglyceridemia in these mice, and thus could be a potential new therapy for apoC-II deficiency.
  • Yuji Takahashi, Yasuki Ito, Norio Wada, Atsushi Nagasaka, Masato Fujikawa, Toshihiro Sakurai, Rojeet Shrestha, Shu-Ping Hui, Hitoshi Chiba
    CLINICA CHIMICA ACTA 454 135 - 142 2016年02月 [査読有り][通常論文]
     
    Background: Pathophysiological role for high-density lipoprotein (HDL) subclasses remains to be elucidated. Homogeneous assay for simultaneous measurements of apoE-deficient HDL-cholesterol (HDL-C), apoE-containing HDL-.C, and total HDL-C is desired, because apoE plays important roles in lipid metabolism. Methods: The proposed assay consists of a primary reaction to remove non-HDL-C, a secondary reaction to measure apoE-deficient HDL-C, and a tertiary reaction to measure apoE-containing HDL-C. The assay is completed within 10 min. For control study, 13% polyethylene glycol precipitation assay and phosphotungstate-dextran sulfate -magnesium precipitation assay were carried out. Results: Good correlations between the control assays and the proposed assay was obtained in serum samples from patients without liver disease (n = 33): r = 0.987, 0.957, and 0.991 for apoE-deficient, apoE-containing, and total HDL-C, respectively. ApoE-containing HDL-C by the proposed method in healthy individuals (n = 12) and patients with hyper-HDL-cholesterolemia (n = 5) were 0.11 +/- 0.03 and 0.26 +/- 0.05 mmol/l (4.1 +/- 1.3 and 10.1 +/- 2.0 mg/dl), respectively. ApoE-containing HDL-C increased rapidly at >2.59 mmol/l (100 mg/dl) of total HDL-C, suggesting a unique regulating mechanism of apoE-containing HDL-C. Conclusions: The established homogeneous assay might be useful for clinical and epidemiological studies on apoE-deficient and apoE-containing HDL subclasses. (C) 2016 Elsevier B.V. All rights reserved.
  • Marcelo J. A. Amar, Toshihiro Sakurai, Akiko Sakurai-Ikuta, Denis Sviridov, Lita Freeman, Lusana Ahsan, Alan T. Remaley
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 352 2 227 - 235 2015年02月 [査読有り][通常論文]
     
    Apolipoprotein A-I (apoA-I) mimetic peptides are currently being developed as possible new agents for the treatment of cardiovascular disease based on their ability to promote cholesterol efflux and their other beneficial antiatherogenic properties. Many of these peptides, however, have been reported to cause transient hypertriglyceridemia due to inhibition of lipolysis by lipoprotein lipase (LPL). We describe a novel bihelical amphipathic peptide (C-II-a) that contains an amphipathic helix (18A) for binding to lipoproteins and stimulating cholesterol efflux as well as a motif based on the last helix of apolipoprotein C-II (apoC-II) that activates lipolysis by LPL. The C-II-a peptide promoted cholesterol efflux from ATP-binding cassette transporter ABCA1-transfected BHK cells similar to apoA-I mimetic peptides. Furthermore, it was shown in vitro to be comparable to the full-length apoC-II protein in activating lipolysis by LPL. When added to serum from a patient with apoC-II deficiency, it restored normal levels of LPL-induced lipolysis and also enhanced lipolysis in serum from patients with type IV and V hypertriglyceridemia. Intravenous injection of C-II-a (30 mg/kg) in apolipoprotein E-knockout mice resulted in a significant reduction of plasma cholesterol and triglycerides of 38 +/- 6% and 85 +/- 7%, respectively, at 4 hours. When coinjected with the 5A peptide (60 mg/kg), the C-II-a (30 mg/kg) peptide was found to completely block the hypertriglyceridemic effect of the 5A peptide in C57Bl/6 mice. In summary, C-II-a is a novel peptide based on apoC-II, which promotes cholesterol efflux and lipolysis and may therefore be useful for the treatment of apoC-II deficiency and other forms of hypertriglyceridemia.
  • Rojeet Shrestha, Shu-Ping Hui, Toshihiro Sakurai, Akiko Yagi, Yuji Takahashi, Seiji Takeda, Shigeki Jin, Hirotoshi Fuda, Hitoshi Chiba
    ANNALS OF CLINICAL BIOCHEMISTRY 51 6 662 - 671 2014年11月 [査読有り][通常論文]
     
    Background Oxidation of lipoproteins is thought to play a crucial role in atherogenesis. Role for triglyceride-rich lipoproteins in atherogenesis is unclear. Thus, we aimed to investigate whether cholesteryl ester hydroperoxides (CEOOH) are present in very low-density lipoproteins (VLDL) and intermediate-density lipoproteins (IDL) by using highly sensitive liquid chromatography/mass spectrometry. Methods Total lipids were extracted from the plasma of healthy donors (n=6) and their fractions of VLDL and IDL. Additional three plasma samples were analysed freshly for CEOOH. Detection and identification of CEOOH was conducted by liquid chromatography/LTQ ion trap mass spectrometry/Orbitrap high mass accuracy mass spectrometry. Authentic standards of CEOOH were used for unequivocal identification on the basis of their mass spectra. Results We identified six molecular CEOOH species overall, namely, Ch18:1-OOH, Ch18:2-OOH, Ch18:3-OOH, Ch20:4-OOH, Ch20:5-OOH and Ch22:6-OOH. Of them, Ch18:2-OOH, Ch20:5-OOH, Ch20:4-OOH and Ch22:6-OOH were detected in all IDL samples, while only Ch20:4-OOH was detected in all VLDL samples. All of CEOOH species except for Ch18:3-OOH were detected in plasma, with constant detection of Ch20:5-OOH, and Ch22:6-OOH in all plasma samples. Conclusion The presence of CEOOH species in VLDL and IDL was confirmed with the analytical sensitivity of 0.1pmol, showing the constant appearance of more CEOOH species in IDL than VLDL. This finding might add biochemical evidences of atherogenicity of these lipoproteins. Clinical utility of measuring CEOOH level in these lipoproteins need to be investigated for the risk assessment of the cardiovascular disease.
  • Megumi Nishimukai, Ryouta Maeba, Akiko Ikuta, Naoya Asakawa, Kiwamu Kamiya, Shiro Yamada, Takashi Yokota, Mamoru Sakakibara, Hiroyuki Tsutsui, Toshihiro Sakurai, Yuji Takahashi, Shu-Ping Hui, Hitoshi Chiba, Tomoki Okazaki, Hiroshi Hara
    CLINICA CHIMICA ACTA 437 147 - 154 2014年11月 [査読有り][通常論文]
     
    Background: Identifying risk factors is crucial for preventing cardiovascular events, but there are no widely accepted predictive biomarkers. In our previous study of Japanese asymptomatic cohorts, we performed global analysis of serum ether glycerophospholipids (Egp) molecular profiles, and found that choline plasmalogens (PlsCho; 1-O-alk-1'-enyl-2-acyl-sn-glycero-3-phosphocholine), particularly those containing oleic acid (18:1) in the sn-2 position, were strongly associated with a wide range of risk factors for metabolic syndrome/atherosclerosis. Methods: We determined serum concentrations of Egp molecular species of coronary artery disease patients (n = 50; 31 males and 19 females) by LC/MS/MS, and plasmalogen (Pls; 1-O-alk-1'-enyl-2-acyl-sn-glycerophospholipids) contents in lipoprotein fractions by HPLC using radioactive iodine. Results: We found that the serum concentrations of ether choline glycerophospholipids (EgpCho), particularly PlsCho, were not only significantly lower in males with significant coronary stenosis but also associated with atherosclerosis-related parameters, and their association was stronger than either high-density lipoprotein cholesterol or adiponectin. In addition, serum PlsCho containing 18:1 or linoleic acid (18:2) in sn-2 showed the highest correlations with a wide range of atherogenic parameters among PlsCho molecular species. Conclusion: These results verify our previous findings that serum PlsCho, particularly those containing 18:1 in sn-2, may serve as reliable biomarkers for atherosclerosis. (C) 2014 Elsevier B.V. All rights reserved.
  • Hironori Nagasaka, Hirokazu Tsukahara, Yoshiyuki Okano, Ken-ichi Hirano, Toshihiro Sakurai, Shu-Ping Hui, Toshihiro Ohura, Hiromi Usui, Tohru Yorifuji, Satoshi Hirayama, Akira Ohtake, Takashi Miida
    CLINICA CHIMICA ACTA 433 1 - 4 2014年06月 [査読有り][通常論文]
     
    Background: Influence of hyperphenylalaninemia on lipoproteins in early life remains unclear. Methods: We enrolled 24 phenylalanine hydroxylase (PAH)-deficient children who were classified into a phenylketonuria (PKU) group (n = 12) lacking PAH activity and a benign hyperphenylalaninemia (HPA) group (n = 12) having partial PAH activity, and their 11 non-affected siblings. We measured serum total-cholesterol, low-density lipoprotein (LDL)-cholesterol, and high-density lipoprotein (HDL)-cholesterol levels together with apolipoproteins for the first year of life, and compared them with those of 30 age-matched healthy controls. Results: The affected groups invariably had lower cholesterol levels than non-affected groups. At birth, HDL-cholesterol decrease was greatest and predominated over the LDL-cholesterol decrease: total cholesterol, 28/36% decrease to the control level in HPA/PKU; HDL-cholesterol, 33/51%; LDL-cholesterol, 20/28%. At 3 months, the opposite changes were observed: total cholesterol, 16/28%; HDL-cholesterol, 13/23%; LDL-cholesterol, 16/33%. At 12 months, LDL were still significantly lower in both groups (8/18%, p < .05 and .001), although HDL was significantly decreased only in the PKU group (15%, p < .05). Apolipoprotein A-I/A-II and B changed respectively in accordance with HDL-cholesterol and LDL-cholesterol changes. Despite similar phenylalanine levels, the PKU group invariably had lower cholesterol concentrations than the HPA group had. Conclusion: Irrespective of phenylalanine concentrations, lipoprotein synthesis in PAH-deficient children, particularly in PKU children, was suppressed in early life. (C) 2014 Elsevier B.V. All rights reserved.
  • Megumi Nishimukai, Ryouta Maeba, Yuya Yamazaki, Toru Nezu, Toshihiro Sakurai, Yuji Takahashi, Shu-Ping Hui, Hitoshi Chiba, Tomoki Okazaki, Hiroshi Hara
    JOURNAL OF LIPID RESEARCH 55 5 956 - 965 2014年05月 [査読有り][通常論文]
     
    Serum plasmalogens (Pls) (1-O-alk-1'-enyl-2-acyl glycerophospholipids) are of particular interest for studies on metabolic disorders associated with oxidative stress and chronic inflammation. Serum levels of Pls are known to correlate positively with HDL-cholesterol (HDL-C); however, few studies have examined serum Pls molecular species in association with pathophysiological conditions and their clinical significance. To clarify these, we determined serum levels of individual ether glycerophospholipids in Japanese asymptomatic cohorts (n = 428; 362 male and 66 female subjects) by LC/MS/MS, and examined their correlations with clinical parameters. We found that the proportion of choline Pls (PlsCho) among total serum phospholipids was significantly lower in the male group over 40 years old and was associated with multiple risk parameters more strongly than HDL-C. The abundance of serum PlsCho with oleic acid (18:1) in sn-2 exhibited the strongest positive correlation with serum concentrations of adiponectin and HDL-C, while being inversely associated with waist circumference and the serum levels of TG and small dense LDL-cholesterol. The characterization of serum ether glycerophospholipids verified the specificity of PlsCho, particularly the ones with 18:1 in sn-2, as a sensitive biomarker for the atherogenic state.
  • Futaba Ohkawa, Seiji Takeda, Shu-Ping Hui, Toshihiro Sakurai, Shigeki Jin, Hirotoshi Fuda, Kazuhisa Sueoka, Hitoshi Chiba
    IEEE SENSORS JOURNAL 14 2 532 - 537 2014年02月 [査読有り][通常論文]
     
    In this paper, a novel method for evaluating antioxidant activity against low density lipoprotein (LDL) oxidation (anti-LDLox) using a carbon nanotube (CNT) based electrode was investigated. Although ORAC and DPPH are known methods to evaluate antioxidant activity, they do not directly reflect the capacities of anti-LDLox. A method has been reported for measuring oxidized LDL using a CNT electrode. We evaluated anti-LDLox by measuring the amount of oxidized LDL using the electrode after incubation of LDL with antioxidants during copper-mediated oxidation. Thiobarbituric acid reactive substances (TBARS) were also determined for comparison with the CNT electrode. There was a correlation of the CNT electrode with the TBARS and the ORAC, whereas no correlation was found between the CNT electrode and the DPPH. We demonstrate here that a CNT electrode method has a potential for the determination of the antioxidant activity of various natural and synthetic compounds by detecting oxidized LDL.
  • Toshihiro Sakurai, Seiji Takeda, Jun-ya Takahashi, Yuji Takahashi, Norio Wada, Suchin Trirongjitmoah, Takeshi Namita, Shigeki Jin, Akiko Ikuta, Hiroaki Furumaki, Shu-Ping Hui, Hirotoshi Fuda, Masato Fujikawa, Koichi Shimizu, Hitoshi Chiba
    ANNALS OF CLINICAL BIOCHEMISTRY 50 6 564 - 570 2013年11月 [査読有り][通常論文]
     
    Background The size of lipoprotein particles is relevant to the risk of coronary artery disease (CAD). Methods We investigated the feasibility of atomic force microscopy (AFM) for evaluating the size of large low-density lipoprotein (LDL) and small dense LDL (sd-LDL) separated by ultracentrifugation. The measurements by AFM in tapping mode were compared to those by electron microscopy (EM). Results There was a significant difference in particle sizes determined by AFM between large LDL (20.61.9nm, mean +/- SD) and sd-LDL (16.2 +/- 1.4nm) obtained from six healthy volunteers (P<0.05). The particle sizes determined by EM for the same samples were 23.2 +/- 1.4nm for large LDL and 20.4 +/- 1.4nm for sd-LDL. The difference between large LDL and sd-LDL detected by EM was also statistically significant (P<0.05). In addition, the particle sizes of each lipoprotein fraction were significantly different between AFM and EM: P<0.05 for large LDL and P<0.05 for sd-LDL. Conclusions AFM can differentiate between sd-LDL and large LDL particles by their size, and might be useful for evaluating risk for CAD.
  • Seiji Takeda, Futaba Ohkawa, Shu-Ping Hui, Toshihiro Sakurai, Shigeki Jin, Hirotoshi Fuda, Kazuhisa Sueoka, Hitoshi Chiba
    IEEE SENSORS JOURNAL 13 9 3449 - 3453 2013年09月 [査読有り][通常論文]
     
    Oxidized-low-density lipoprotein (ox-LDL), which is generated by LDL oxidation, is a risk factor of cardiovascular disease development. LDL has positive charges on the surface attributable to amino groups of lysine moieties on Apo B-100. Its positive charge is decreased by oxidation. For this paper, the topography and surface potential of LDL and ox-LDL are measured using atomic force microscopy and Kelvin probe force microscopy (KPFM). Although it is difficult to ascertain a difference between topographic images of LDL and ox-LDL, the KPFM images of ox-LDL differ from those obtained using LDL. The averaged potential of the surface decreases concomitantly with increasing oxidation time of the LDL. We demonstrate a method to evaluate the oxidation level of LDL using KPFM.
  • Shigeki Jin, Norio Wada, Yuji Takahashi, Shu-Ping Hui, Toshihiro Sakurai, Hirotoshi Fuda, Seiji Takeda, Masato Fujikawa, Katsuyuki Yanagisawa, Shigeo Ikegawa, Takao Kurosawa, Hitoshi Chiba
    ANNALS OF CLINICAL BIOCHEMISTRY 50 5 450 - 456 2013年09月 [査読有り][通常論文]
     
    Background: Urinary 18-hydroxycortisol has been investigated as a marker of aldosterone-producing adenoma (APA). The aim of this study was to develop and validate a method for the measurement of 18-hydroxycortisol using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Methods: Urine was collected over a 24-hour period in patients with APA (n=11), idiopathic hyperaldosteronism (IHA, n=9), and essential hypertension (EH, n=6). 18-Hydroxycortisol was extracted in solid-phase, and measured by LC-MS/MS based on selected reaction monitoring. Results: The method allowed quantification of 18-hydroxycortisol with a lower quantification limit of 0.26nmol/L, intra- and inter-assay coefficients of variation of <3.4% and a range of analytical recovery of 98.0-103.7%. Urinary 18-hydroxycortisol excretion for APA, IHA and EH were determined as 725 (SD 451), 102 (SD 68) and 88 (SD 76) nmol/day, respectively. Conclusions: The proposed method met the basic analytical requirements and was considered to be useful in the screening and differential diagnosis of APA.
  • Toshihiro Sakurai, Norio Wada, Yuji Takahashi, Ayako Ichikawa, Akiko Ikuta, Hiroaki Furumaki, Shu-Ping Hui, Shigeki Jin, Seiji Takeda, Hirotoshi Fuda, Masato Fujikawa, Chikara Shimizu, Hironori Nagasaka, Hiroyuki Furukawa, Seiichi Kobayashi, Hitoshi Chiba
    ANNALS OF CLINICAL BIOCHEMISTRY 50 5 465 - 472 2013年09月 [査読有り][通常論文]
     
    Background: Triglyceride-rich, low-density lipoproteins (TG-rich LDL) have been reported as an oxidized lipoprotein species in patients with severe liver disease. Using TG-rich LDL as an immunogen, we obtained a monoclonal antibody (G11-6) that reacted with TG-rich LDL from patients with liver disease and with metal-oxidized LDL only in the early process of the oxidation reaction. This study determined the G11-6-reactive lipoproteins in hypertriglyceridemic serum. Methods: Serum samples from healthy volunteers (n=12) and hypertriglyceridemic patients (n=9) were fractionated by gel filtration and subjected to a sandwich enzyme-linked immunosorbent assay (ELISA) using G11-6 and polyclonal anti-apolipoprotein B antibodies. Results: Small LDL and larger lipoproteins reacted with G11-6. G11-6-reactive small LDL was identified in both the healthy subjects and hypertriglyceridemic patients, whereas G11-6-reactive larger lipoproteins were found only in the hypertriglyceridemic patients. Conclusions: G11-6 is a useful tool for detecting increased large oxidized lipoproteins in hypertriglyceridemic patients.
  • Hui SP, Sakurai T, Takeda S, Jin S, Fuda H, Kurosawa T, Chiba H
    Analytical and bioanalytical chemistry 405 14 4981 - 4987 2013年05月 [査読有り][通常論文]
  • Takeda S, Hui SP, Fuda H, Jin S, Sakurai T, Ishii A, Mukasa K, Sueoka K, Chiba H
    Journal of biomedical nanotechnology 9 2 303 - 306 2013年02月 [査読有り][通常論文]
  • Kazuya Iinaga, Takeshi Namita, Toshihiro Sakurai, Hitoshi Chiba, Koichi Shimizu
    2013 35TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY (EMBC) 2013 1214 - 1217 2013年 [査読有り][通常論文]
     
    To find an early symptom of postprandial hyperlipidemia, we developed a technique to measure the change in triglyceride noninvasively. We examined the feasibility to measure the change in the triglyceride concentration as the change in the scattering coefficient of the blood. In an experiment, good correlation was obtained between the change in the triglyceride after a meal and the optical change. This suggested the feasibility of the noninvasive measurement of the triglyceride in blood.
  • Mitsugu Watanabe, Hirotoshi Fuda, Shigeki Jin, Toshihiro Sakurai, Shu-Ping Hui, Seiji Takeda, Takayuki Watanabe, Takao Koike, Hitoshi Chiba
    FOOD CHEMISTRY 134 4 2086 - 2089 2012年10月 [査読有り][通常論文]
     
    3,5-Dihydroxy-4-methoxybenzyl alcohol (DHMBA), an antioxidant isolated from the Pacific oyster (Crassostrea gigas), was studied in a cell-based fluorometric antioxidant assay using human hepatocyte-derived cells (C3A) and diphenyl-1-pyrenylphosphine (DPPP) as a fluorescent probe. In comparison with two hydrophilic antioxidants. DHMBA showed the stronger inhibition of DPPP-mediated fluorescence than chlorogenic acid and L-ascorbic acid: at a concentration of 320 mu M of DPPP, the inhibition was 26.4 +/- 2.6%, 11.1 +/- 1.2%, and 0 +/- 2.0% for DHMBA, chlorogenic acid, and L-ascorbic acid, respectively (mean +/- SD, n = 4). Their relative oxygen radical absorbance capacities (ORAC) were dissociated with their cell-based antioxidant activities: 1.47 +/- 0.40, 4.57 +/- 0.30, and 0.53 +/- 0.13 mu mol TE/mu mol for DHMBA, chlorogenic acid, and L-ascorbic acid, respectively (mean +/- SD, n = 4). The amphiphilicity of DHMBA was better than chlorogenic acid and L-ascorbic acid might underlie this dissociation. Since the C3A cells are human hepatoma-derived cells, DHMBA might be useful in the prevention and treatment of liver diseases by involving an oxidation process. (C) 2012 Elsevier Ltd. All rights reserved.
  • Toshihiro Sakurai, Ayako Ichikawa, Hiroyuki Furukawa, Norio Wada, Atsushi Nagasaka, Yuji Takahashi, Masato Fujikawa, Akiko Ikuta, Hiroaki Furumaki, Maiko Shiga, Chikara Shimizu, Shu-Ping Hui, Shigeki Jin, Seiji Takeda, Hirotoshi Fuda, Hironori Nagasaka, Seiichi Kobayashi, Hitoshi Chiba
    ANNALS OF CLINICAL BIOCHEMISTRY 49 Pt 5 456 - 462 2012年09月 [査読有り][通常論文]
     
    Background: Triglyceride-rich low-density lipoproteins (TG-rich LDLs) in the plasma of patients with severe liver disease are reported to change macrophages into foam cells in vitro. Methods: Male BALB/c mice were immunized with TG-rich LDLs isolated from the plasma of a patient with severe liver disease. The resulting monoclonal antibody (G11-6) was used in a sandwich enzyme-linked immunosorbent assay (ELISA) in combination with polyclonal anti-apolipoprotein B antibodies. The time course of copper-mediated LDL oxidation was monitored using this ELISA. The results were compared with those of the two commercial ELISAs for oxidized LDLs using DLH or ML25, thiobarbituric acid reactive substances and the optical absorbance for the conjugated dienes generated in lipid peroxides. Furthermore, the lipoprotein fractions separated by gel filtration were tested with this ELISA in healthy volunteers (n = 11) and patients (n = 3) with liver disease. Results: G11-6 reacted with oxidized LDLs during only the early phase of copper oxidation, being distinct from the other monoclonal antibodies and methods. G11-6 was confirmed to react with TG-rich LDLs in patients, while it reacted with small LDL particles in normal controls. Conclusions: The monoclonal antibody G11-6 is useful for detecting oxidized small LDLs in normal controls and oxidized TG-rich LDLs in patients with severe liver disease.
  • Shu-Ping Hui, Toshihiro Sakurai, Futaba Ohkawa, Hiroaki Furumaki, Shigeki Jin, Hirotoshi Fuda, Seiji Takeda, Takao Kurosawa, Hitoshi Chiba
    ANALYTICAL AND BIOANALYTICAL CHEMISTRY 404 1 101 - 112 2012年07月 [査読有り][通常論文]
     
    Oxidation of cholesteryl esters in lipoproteins by reactive oxygen species yields cholesteryl ester hydroperoxides (CEOOH). In this study, we developed a novel method for identification and characterization of CEOOH molecules in human lipoproteins by use of reversed-phase liquid chromatography with an hybrid linear ion trap-Orbitrap mass spectrometer (LC-LTQ Orbitrap). Electrospray ionization tandem mass spectrometric analysis was performed in both positive-ion and negative-ion modes. Identification of CEOOH molecules was completed by use of high-mass-accuracy (MA) mass spectrometric data obtained by using the spectrometer in Fourier-transform (FT) mode. Native low-density lipoproteins (nLDL) and native high-density lipoproteins (nHDL) from a healthy donor were oxidized by CuSO4, furnishing oxidized LDL (oxLDL) and oxidized HDL (oxHDL). No CEOOH molecules were detected in the nLDL and the nHDL, whereas six CEOOH molecules were detected in the oxLDL and the oxHDL. In positive-ion mode, CEOOH was detected as [M + NH4](+) and [M + Na](+) ions. In negative-ion mode, CEOOH was detected as [M + CH3COO](-) ions. CEOOH were more easily ionized in positive-ion mode than in negative-ion mode. The LC-LTQ Orbitrap method was applied to human plasma and six species of CEOOH were detected. The limit of detection was 0.1 pmol (S/N = 5:1) for synthesized CEOOH.
  • Shu-Ping Hui, Yudai Taguchi, Seiji Takeda, Futaba Ohkawa, Toshihiro Sakurai, Shinobu Yamaki, Shigeki Jin, Hirotoshi Fuda, Takao Kurosawa, Hitoshi Chiba
    ANALYTICAL AND BIOANALYTICAL CHEMISTRY 403 7 1831 - 1840 2012年06月 [査読有り][通常論文]
     
    1-Palmitoyl-2-linoleoylphosphatidylcholine monohydroperoxide (PC 16:0/18:2-OOH) and 1-stearoyl-2-linoleoylphosphatidylcholine monohydroperoxide (PC 18:0/18:2-OOH) were measured by liquid chromatography/mass spectrometry (LC/MS) using nonendogenous 1-palmitoyl-2-heptadecenoylphosphatidylcholine monohydroperoxide as an internal standard. The calibration curves for synthetic PC 16:0/18:2-OOH and PC 18:0/18:2-OOH, which were obtained by direct injection of the internal standard into the LC/MS system, were linear throughout the calibration range (0.8-12.8 pmol). Within-day and between-day coefficients of variation were less than 10%, and the recoveries were between 86% and 105%. The limit of detection (LOD) and the limit of quantification (LOQ) were determined using synthetic standards. The LOD (signal-to-noise ratio 3:1) was 0.01 pmol, and the LOQ (signal-to-noise ratio 6:1) was 0.08 pmol for both PC 16:0/18:2-OOH and PC 18:0/18:2-OOH. With use of this method, the concentrations of PC 16:0/18:2-OOH and PC 18:0/18:2-OOH in the lipoprotein fractions during copper-mediated oxidation were determined. We prepared oxLDL and oxHDL by incubating native LDL and native HDL from human plasma (n = 10) with CuSO4 for up to 4 h. The time course of the PC 16:0/18:2-OOH and PC 18:0/18:2-OOH levels during oxidation consisted of three phases. For oxidized LDL, both compounds exhibited a slow lag phase and a subsequent rapidly increasing propagation phase, followed by a gradually decreasing degradation phase. In contrast, for oxidized HDL, both compounds initially exhibited a prompt propagation phase with a subsequent plateau phase, followed by a rapid degradation phase. The analytical LC/MS method for phosphatidylcholine hydroperoxides might be useful for the analysis of biological samples.
  • Seiji Takeda, Shu-Ping Hui, Keisuke Fukuda, Hirotoshi Fuda, Shigeki Jin, Toshihiro Sakurai, Atsushi Ishii, Koichi Mukasa, Kazuhisa Sueoka, Hitoshi Chiba
    SENSORS AND ACTUATORS B-CHEMICAL 166 833 - 836 2012年05月 [査読有り][通常論文]
     
    Oxidized low-density lipoproteins (LDLs) play a key role in cardiovascular disease development, but no convenient measurement method is available for them. Using a carbon nanotube (CNT) electrode, we measured oxidized LDL using amperometric detection. Treating SWCNT with a mixture of acids produced a CNT dispersion that yielded nanotube-based electrodes after deposition on a gold electrode and drying. Current was monitored in the nanotube electrode before and after adding LDL or oxidization of LDL Oxidized LDL changed the current more than 10 nA, although LDL addition induced no significant change. Our CNT electrode enables simple detection of oxidized LDL. (C) 2012 Elsevier B.V. All rights reserved.
  • Yin Lin, Hiroaki Furumaki, Shiho Matsuoka, Toshihiro Sakurai, Masashi Kohanawa, Songji Zhao, Yuji Kuge, Nagara Tamaki, Hitoshi Chiba
    LABORATORY INVESTIGATION 92 2 265 - 281 2012年02月 [査読有り][通常論文]
     
    Not-alcoholic steatohepatitis (NASH) is the hepatic manifestation of metabolic syndrome that is characterized by steritosis, inflammation, and fibrosis, and may progress to cirrhosis and carcinoma. To investigate its pathogenic processes, we established a novel murine model for NASH by combination of a high-fat diet (HFD) and oxidized low-density lipoprotein (oxLDL). Mice that received HFD for 23 weeks showed hepatic steatosis, slight fibrosis, and a high level of lipid peroxidation compared with a regular diet (RD)-fed mice. Hepatic injury and elevated tumor necrosis factoor (TNF)-alpha mRNA expression were also detected in these mice. Moreover, oxLDL administration to HFD-fed mice during weeks 21-23 not only aggravated hepatic steatosis, fibrosis, and lipid metabolism, but also resulted in intense inflammation, including severe hepatic injury and inflammatory cell infiltration, which are the typical histological features of NASH. Inflammation was accompanied by increased gene expression of TNF-alpha and interleukin (IL)-6. Additionally, the livers of RD-fed animals treated with oxLDL during weeks 21-23 were characterized by foamy macrophages and inflammatory cell infiltration along with an elevated IL-6 mRNA level. These results suggest that an increased oxidative state, including HFD-induced intracellular lipid peroxidation and its extracellular source from oxLDL, is the actual trigger for hepatic inflammation in which liver injury is mediated by TNF-alpha: and inflammatory cell accumulation is dependent on HFD and oxLDL also induced insulin resistance in mice; additionally, oxLDL downregulated insulin secretion. In his model, CD36 overexpression was observed in the hepatocytes of HFD-fed mice and those treated with HFD and oxl DL, and in the hepatic macrophages of RD-fed mice immediately after oxLDL treatment. In vitro experiments indicated a rapid and transient elevation of CD36 on macrophage plasma membrane in response to oxLDL. Our findings demonstrate that CD36 expressed on hepatocytes and hepatic macrophages mediates the pathophysiology of NASH. Laboratory Investigation (2012) 92, 265-281; doi:10.1038/labinvest.2011.159; published online 7 November 2011
  • Mitsugu Watanabe, Hirotoshi Fuda, Shigeki Jin, Toshihiro Sakurai, Futaba Ohkawa, Shu-Ping Hui, Seiji Takeda, Takayuki Watanabe, Takao Koike, Hitoshi Chiba
    JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 60 3 830 - 835 2012年01月 [査読有り][通常論文]
     
    Using an oxygen radical absorbance capacity (ORAC) assay, antioxidant activity was detected in the ethanol extract of the Pacific oyster, which was purified by sequential extraction with organic solvents. The ethyl acetate fraction showed the strongest antioxidant activity and was further purified, yielding a single compound [as assessed by thin-layer chromatography (TLC) reverse-phase high-performance liquid chromatography (HPLC)]. This compound was identified as 3,5-dihydroxy4-metboxybenzyl alcohol on the basis of H-1 and C-13 nuclear magnetic resonance (NMR), heteronuclear multiple-bond correlz.tion (HMBC), and electrospray ionization-mass spectrometry (ESI-MS) spectral analyses, a conclusion that was confirmed bycheinical synthesis. The concentration of the compound was 6.7 mg/100 g of whole oyster meat wet weight. This azaphi'philic gritiosidant retarded the copper mediated oxidation of low density lipoproteins (LDLs) and the generation of,tr.ickarbitonc acid.teactive substances. Furthermore, the compound showed substantial antioxidant activity using the ORAC and 2,2-diphenyl-1-picrythy'drazyl (DPPH) assays compared to natural antioxidants. Although the same compound was previously found in brown algae, its presence in other organisms and antioxidant activity are reported here for the first time.
  • Toshihiro Sakurai, Suchin Trirongjitmoah, Yuka Nishibata, Takeshi Namita, Masahiro Tsuji, Shu-Ping Hui, Shigeki Jin, Koichi Shimizu, Hitoshi Chiba
    ANNALS OF CLINICAL BIOCHEMISTRY 47 Pt 5 476 - 481 2010年09月 [査読有り][通常論文]
     
    Background: A simple method for the measurement of LDL particle sizes is needed in clinical laboratories because a predominance of small, dense LDL (sd LDL) has been associated with coronary heart disease. We applied dynamic light scattering (DLS) to measure lipoprotein particle sizes, with special reference to sd LDL. Methods: Human serum lipoproteins isolated by a combination of ultracentrifugation and gel chromatography, or by sequential ultracentrifugation, were measured for particle size using DLS. Results: The sizes of polystyrene beads, with diameters of 21 and 28 nm according to the manufacturer, were determined by DLS as 19.3 +/- 1.0 nm (mean +/- SD, n = 11) and 25.5 +/- 1.0 nm, respectively. The coefficients of variation for the 21 and 28 nm beads were 5.1% and 3.8% (within-run, n = 11), and 2.9% and 6.2% (between-run, n = 3), respectively. The lipoprotein sizes determined by DLS for lipoprotein fractions isolated by chromatography were consistent with the elution profile. Whole serum, four isolated lipoprotein fractions (CM + VLDL + IDL, large LDL, sd LDL and HDL) and a non-lipoprotein fraction isolated by sequential ultracentrifugation were determined by DLS to be 13.1 +/- 7.5, 37.0 +/- 5.2, 21.5 +/- 0.8, 20.3 +/- 1.1, 8.6 +/- 1.5 and 8.8 +/- 2.0 nm, respectively. Conclusions: The proposed DLS method can differentiate the sizes of isolated lipoprotein particles, including large LDL and sd LDL, and might be used in clinical laboratories in combination with convenient lipoprotein separation.
  • Suchin Trirongjitmoah, Toshihiro Sakurai, Kazuya Iinaga, Hitoshi Chiba, Koichi Shimizu
    OPTICS EXPRESS 18 6 6315 - 6326 2010年03月 [査読有り][通常論文]
     
    Small, dense low-density lipoprotein (sdLDL) in total LDL is strongly related with the cardiovascular risk level. An optical technique using dynamic light scattering (DLS) measurement is useful for point-of-care testing of sdLDL. However, the sdLDL fraction estimated from the particle size distribution in DLS data is sensitive to noise and artifacts. Therefore, we derived analytical solutions in a closed form to estimate the fraction of scatterers using the autocorrelation function of scattered light from a polydisperse solution. The effect of the undesired large particles can be eliminated by the pre-processing of the autocorrelation function. The proposed technique was verified using latex standard particles and LDL solutions. Results suggest the feasibility of this technique to estimate the sdLDL fraction using optical scattering measurements. (C) 2010 Optical Society of America
  • Shu-Ping Hui, Hitoshi Chiba, Toshihiro Sakurai, Chitose Asakawa, Hironori Nagasaka, Tsuyoshi Murai, Hajime Ide, Takao Kurosawa
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES 857 1 158 - 163 2007年09月 [査読有り][通常論文]
     
    Quantitative and qualitative analyses of 1-palmitoyl-2-linoleoyl-phosphatidylcholne monohydroperoxide [PC 16:0/18:2-OOH] and 1-stearoyl-2-linoleoyl-phosphatidylcholine monohydroperoxide [PC 18:0/18:2-OOH] in human plasma were improved by chemiluminescence HPLC using synthetic 1-stearoyl-2-erucoyl-phosphatidylcholine monohydroperoxide (PC 18:0/22:1-OOH) as internal standard. The calibration curves of synthetic PC 16:0/18:2-OOH and PC 18:0/18:2-OOH, obtained by their direct injections with the IS into the HPLC system, were linear throughout the calibration range (10-1000 pmol). Within-day and between-day coefficients of variation were below 8%, and the recoveries were between 84% and 101%. Plasma concentrations of PC 16:0/18:2-OOH and PC 18:0/18:2-OOH were 102 +/- 59 nM (mean +/- SD) and 36 +/- 120 nM. respectively, in the 33 healthy volunteers. The present method might help understanding incompletely understood pathway of plasma phosphatidylcholine hydroperoxides. (c) 2007 Elsevier B.V. All rights reserved.

書籍

  • 知っておきたい臨床検査値 第2版
    櫻井 俊宏, 高橋 祐司, 分担執筆, 範囲, 章, 梅毒血清 (範囲:櫻井 俊宏, 高橋 祐司 (担当: 分担執筆, 範囲: 第12章 梅毒血清反応))
    東京化学同人 2019年03月
  • Medical Technology
    櫻井 俊宏 (担当:共著範囲:Small dense LDL)
    医歯薬出版 2010年12月

講演・口頭発表等

  • LDL-TG測定試薬の臨床検体への応用  [通常講演]
    櫻井 俊宏
    第58回日本臨床化学会年次学術集会 若手育成シンポジウム 2018年08月 シンポジウム・ワークショップパネル(指名)
  • 研究留学を振り返って  [通常講演]
    櫻井 俊宏
    北海道大学大学院保健科学研究院 保健科学セミナー 2016年06月 公開講演,セミナー,チュートリアル,講習,講義等
  • Efficacy of apoC-II mimetic peptide in novel Apoc2 mutant mice with hypertriglyceridemia and impaired insulin sensitivity  [通常講演]
    Toshihiro Sakurai
    Arteriosclerosis, Thrombosis and Vascular Biology/Peripheral Vascular Disease Annual Conference 2016年05月
  • Injection of apoC-II mimetic peptide normalizes triglycerides in apoC-II knockout mice, a new model of hypertriglyceridemia  [通常講演]
    Toshihiro Sakurai
    NHLBI DIR Research Festival 2015 2015年06月 口頭発表(一般)
  • Increase of oxidized lipoproteins in liver disease, detected by monoclonal antibody recognizing early lipoprotein change during copper-oxidation  [通常講演]
    Toshihiro Sakurai
    European atherosclerosis society congress annual conference 2012 2012年05月 ポスター発表
  • 原子間力顕微鏡によるリポ蛋白の1粒子計測  [通常講演]
    櫻井 俊宏
    第44回日本臨床検査医学会北海道支部総会 シンポジウム、パネルディスカッション 2010年10月 シンポジウム・ワークショップパネル(指名)
  • Evaluation of Lipoprotein Particle Sizes Using Dynamic Light Scattering  [通常講演]
    Toshihiro Sakurai
    American Association for Clinical Chemistry annual conference 2010 2010年07月 ポスター発表

その他活動・業績

受賞

  • 2019年10月 第29回日本臨床化学会北海道支部例会 若手優秀演題賞
     
    受賞者: 櫻井 俊宏
  • 2018年09月 第43回日本医用マススペクトル学会年会 若手優秀ポスター賞
     
    受賞者: 櫻井 俊宏
  • 2018年05月 北海道大学大学院保健科学研究院 優秀論文賞
     
    受賞者: 櫻井 俊宏
  • 2016年05月 ATVB Young Investigator Travel Award 2016
     
    受賞者: 櫻井 俊宏
  • 2014年09月 日本臨床化学会 論文賞
     
    受賞者: 櫻井 俊宏
  • 2013年10月 日本臨床検査医学会 若手研究者奨励賞
     
    受賞者: 櫻井 俊宏
  • 2013年03月 北海道大学 保健科学院長賞
     
    受賞者: 櫻井 俊宏
  • 2010年09月 日本臨床化学会学会賞 奨励賞
     
    受賞者: 櫻井 俊宏

共同研究・競争的資金等の研究課題

  • 酸化HDLに焦点を当てたNASHの発症機序の解明と診断マーカーの探索
    日本学術振興会:科研費 若手研究
    研究期間 : 2019年04月 -2022年03月 
    代表者 : 櫻井 俊宏
  • ミトコンドリア代謝の包括的評価系の開発
    北海道大学:令和元年度若手研究加速事業
    研究期間 : 2019年07月 -2020年03月 
    代表者 : 櫻井 俊宏
  • 血中低比重リポ蛋白の性質と生活習慣・代謝異常・動脈硬化に関する地域疫学研究
    日本学術振興会:科研費 基盤研究(B)
    研究期間 : 2017年04月 -2020年03月 
    代表者 : 中村 幸志
  • 酸化リポ蛋白代謝に関連する心疾患診断マーカーの開発
    公益財団法人アステラス病態代謝研究会:平成24年度海外留学助成
    研究期間 : 2013年04月 -2014年03月 
    代表者 : 櫻井 俊宏
  • トリグリセリド代謝に適した新しい酸化ストレスマーカーの開発
    日本学術振興会:特別研究員DC
    研究期間 : 2011年04月 -2013年03月 
    代表者 : 櫻井 俊宏

教育活動情報

主要な担当授業

  • 臨床化学実習Ⅰ
    開講年度 : 2018年
    課程区分 : 学士課程
    開講学部 : 医学部
    キーワード : 実験器具、実験機器、操作法、管理法、検体取り扱い法、保存方法、定量法
  • 臨床化学Ⅰ
    開講年度 : 2018年
    課程区分 : 学士課程
    開講学部 : 医学部
    キーワード : 臨床化学検査法、基準値、臨床的意義
  • 臨床化学Ⅱ
    開講年度 : 2018年
    課程区分 : 学士課程
    開講学部 : 医学部
    キーワード : 生化学検査、蛋白質、非蛋白性窒素、酵素、糖質、脂質、電解質、ビタミン、ホルモン、炎症マーカー、腫瘍マーカー、薬物、遺伝子診断
  • 生体分析学
    開講年度 : 2018年
    課程区分 : 学士課程
    開講学部 : 医学部
    キーワード : 血液、体液、ヘモグロビン、恒常性、エネルギー、ビタミン、蛋白、酵素、遺伝子、ホルモン、栄養、水、電解質、腎臓、肝臓、神経、筋
  • 生化学実習
    開講年度 : 2018年
    課程区分 : 学士課程
    開講学部 : 医学部
    キーワード : ピペット、緩衝液、タンパク質、糖、脂質、DNA、酵素
  • 卒業研究
    開講年度 : 2018年
    課程区分 : 学士課程
    開講学部 : 医学部
    キーワード : 医学研究、臨床検査、研究方法、研究発表、研究論文、生理機能検査、超音波検査
  • 保健生化学
    開講年度 : 2018年
    課程区分 : 学士課程
    開講学部 : 医学部
    キーワード : 臨床検査、生化学検査、検体採取、臨床的意義
  • 臨床検査学
    開講年度 : 2018年
    課程区分 : 学士課程
    開講学部 : 医学部
    キーワード : 一般検査、尿検査、便検査、脳脊髄液検査、採血法、検体処理法
  • 臨床検査学実習Ⅱ
    開講年度 : 2018年
    課程区分 : 学士課程
    開講学部 : 医学部
    キーワード : 採血、一般検査、自動分析装置
  • 遺伝子検査学
    開講年度 : 2018年
    課程区分 : 学士課程
    開講学部 : 医学部
    キーワード : 遺伝子、染色体、PCR法、遺伝子検査、個別医療,染色体検査
  • 食品関係法規
    開講年度 : 2018年
    課程区分 : 学士課程
    開講学部 : 医学部
    キーワード : 食品安全基本法、食品衛生法、JAS法、健康増進法、薬事法、計量法、景品表示法、特定商取引法、製造物責任(PL)法、メディアリテラシー、フードファディズム、サイエンスコミニケーション
  • 臨床検査学実習Ⅰ
    開講年度 : 2018年
    課程区分 : 学士課程
    開講学部 : 医学部
    キーワード : 一般検査、尿検査、便検査、脳脊髄液検査、採血法、検体処理法
  • 検査管理学Ⅰ
    開講年度 : 2018年
    課程区分 : 学士課程
    開講学部 : 医学部
    キーワード : 検査部門の役割、日常検査、検査管理、安全管理
  • 臨床講義Ⅲ
    開講年度 : 2018年
    課程区分 : 学士課程
    開講学部 : 歯学部
    キーワード : 臨床、患者、コデンタルスタッフ、保険
  • 医療安全管理学演習
    開講年度 : 2018年
    課程区分 : 学士課程
    開講学部 : 医学部
    キーワード : 医療安全、検体採取、皮膚病変、鼻腔拭い液、咽頭拭い液、鼻腔吸引液

大学運営

委員歴

  • 2019年09月 - 現在   日本臨床化学会 [JSCC]   リポ蛋白検査専門委員会
  • 2019年04月 - 現在   健康食品管理士会北海道支部   幹事役員
  • 2019年04月 - 現在   日本医用マススペクトル学会 [JSBMS]   評議員
  • 2017年04月 - 現在   日本臨床化学会 [JSCC]   評議員
  • 2016年10月 - 現在   日本臨床化学会 [JSCC] 北海道支部   幹事役員

社会貢献活動

  • 事務局長(第57回日本臨床化学会年会、2017年)
    役割 : 運営参加・支援
  • 事務局長(第43回日本医用マススペクトル学会年会、2018年)
    役割 : 運営参加・支援
  • 事務局長(日本臨床化学会 北海道支部、2018年〜)
    役割 : 運営参加・支援

その他

  • 2018年08月 - 2018年08月  非アルコール性脂肪性肝炎の検出を補助する方法(特願2018-156797) 
    特許出願
  • 2018年08月 - 2018年08月  原発性胆汁性胆管炎の検出を補助する方法(特願2018-156744) 
    特許出願
  • 2014年05月 - 2014年05月  軽度に酸化された酸化低密度リポタンパク質に対するモノクローナル抗体およびこれを産生するハイブリドーマ(出願番号 PCT/JP2011/060376) 
    特許出願・取得に貢献 米国出願番号13/695,043 米国特許番号US8729240B2
  • 2014年04月 - 2014年04月  軽度に酸化された酸化低密度リポタンパク質に対するモノクローナル抗体およびこれを産生するハイブリドーマ(特願2012-512908) 
    特許出願・取得に貢献
  • 2010年02月 - 2010年02月  トリグリセリド高含有低密度リポタンパク質を認識する自己抗体に対するモノクローナル抗体およびこれを産生するハイブリドーマ(特願2010-022076) 
    特許出願・取得に貢献


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.